Gland Pharma Limited — Updates, 05-08-2025: Press Release

Gland Pharma reported strong Q1FY26 results. Consolidated revenue rose 7% YoY to ₹1505.6 Cr, with PAT surging 50% YoY to ₹215.5 Cr. Notably, Cenexi achieved EBITDA breakeven, indicating a successful turnaround. Performance was driven by a robust base business and strategic initiatives. The company launched 12 new molecules, including Liraglutide in new markets, and is aggressively expanding GLP-1/Pen/cartridge capacity from 40 million to 140 million units. Focus remains on complex injectables, with 6 already launched and 3 more for approval. Co-development projects for FY28 commercialization are also underway.